Gearbox Biosciences

Gearbox.bio operates in the biotechnology sector, focusing on innovative solutions for protein production in E. coli without the use of antibiotics. The company serves clients in the pharmaceutical, agricultural, and industrial biotechnology markets, providing them with advanced E. coli strains equipped with proprietary Switcher and Pop Out Plasmid™ technologies. These technologies enable high expression of recombinant proteins while eliminating the need for antibiotics, thus offering a safer and more efficient production process. Gearbox.bio's business model revolves around the development and sale of these specialized E. coli strains, as well as licensing their patented technologies to other biotech firms. Revenue is generated through direct sales, licensing agreements, and potentially through collaborative research and development projects. The company's innovative approach not only enhances protein yield but also addresses significant regulatory and safety concerns associated with antibiotic use in bioproduction.

Keywords: biotechnology, E. coli, protein production, antibiotic-free, recombinant proteins, Switcher technology, Pop Out Plasmid, pharmaceutical, industrial biotech, agricultural biotech.